Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy

BACKGROUND: Docetaxel is one of the most frequently used drugs to treat breast cancer. However, resistance or incomplete response to docetaxel is a major challenge. The aim of this study was to utilize MR metabolomics to identify potential biomarkers of docetaxel resistance in a mouse model for BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: van Asten, Jack JA, Vettukattil, Riyas, Buckle, Tessa, Rottenberg, Sven, van Leeuwen, Fijs, Bathen, Tone F, Heerschap, Arend
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404119/
https://www.ncbi.nlm.nih.gov/pubmed/25890200
http://dx.doi.org/10.1186/s12967-015-0458-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404119/
https://www.ncbi.nlm.nih.gov/pubmed/25890200
http://dx.doi.org/10.1186/s12967-015-0458-4

Ejemplares similares